Conotoxia

Conotoxia Ltd is a Cyprus-based brokerage firm founded on 12 December 2018, with a registered address at ChrysorroiaTissis 11, 3032 Limassol. Although the company’s own description mentions a 2013 registration, official records indicate the current entity was incorporated in 2018. The firm operates primarily as a CFD broker, offering forex trading alongside other instruments.

Publicly available data lists zero employees, which suggests a very small operation or reliance on outsourced services. The broker holds a single CySEC license, which is mandatory for operating in Cyprus and across the EU under MiFID II.

Conotoxia Ltd is regulated by the Cyprus Securities and Exchange Commission (CySEC) under license number 336/17. CySEC is a Tier‑2 regulator within the EU, and its oversight ensures adherence to strict financial standards, including client fund segregation and participation in the Investor Compensation Fund (ICF) up to €20,000. The broker holds a Market Making (MM) license, which permits it to act as a counterparty to client trades.

The license status is not publicly reported, but the registration remains active. Traders should note that CySEC regulation does not guarantee trade execution quality or service reliability, but it does provide a mechanism for dispute resolution and compensation in the event of broker insolvency.

Conotoxia offers three types of trading accounts designed to comply with European Securities and Markets Authority (ESMA) leverage restrictions: Retail, Experienced, and Professional. The minimum deposit for each account is not disclosed, which can make it difficult for traders to assess entry requirements.

The Retail account meets the default ESMA cap of 1:30 leverage for forex, suitable for novice traders seeking limited risk. The Experienced account allows leverage up to 1:100, targeting those with documented trading experience. The Professional account raises leverage to 1:300, available to clients who meet certain financial and experience thresholds but will lose negative balance protection and other retail safeguards.

No information is provided on minimum spreads or commissions, adding a layer of opacity that may concern cost‑conscious traders.

Forex pairs constitute the core offering, but the broker’s own materials indicate an expanded range of CFD instruments covering indices, shares, ETFs, commodities, cryptocurrencies, and futures. This suggests a multi‑asset platform, though the exact number and diversity of instruments are not independently confirmed.

Such variety could appeal to traders looking to diversify, but without transparent asset lists, traders may find it hard to verify liquidity or trading conditions.

Conotoxia does not publicly disclose its supported deposit or withdrawal methods. Typically, CySEC‑regulated brokers offer bank wire, credit/debit cards, and e‑wallets, but the absence of official information leaves potential clients in the dark about funding times and fees.

This lack of transparency contrasts with standard industry practice and may be a red flag for traders who prioritize clear funding procedures.

Given its CySEC license and account‑tier structure, Conotoxia appears to target a broad European audience, from retail beginners (via the Retail account) to experienced professionals seeking higher leverage. However, the missing details on costs and funding methods force interested traders to do extra legwork or contact support before committing.

The broker’s heavy reliance on a single regulatory license and its very small operational footprint suggest it is best suited to traders who are comfortable navigating its opacity and who may already be familiar with the Conotoxia brand.